PPT-ASCO 2010:

Highlights from the Annual Clinical Meeting Gynecologic Cancer Sidney A Scudder MD Professor of Medicine UC Davis Cancer Center Conference Directors Helen Chew MD FACP Primo Lara Jr MD. EXPERIENCE THE VALUE OF ASCOS GLOBAL COMMUNITY The American Society of Clinical Oncology ASCO is the worlds leading professional society of multidisciplinary cancer professionals At ASCO its the unique knowledge and experience each of our nearly 350 The ASCO 7000 ERIES Generator Paralleling Control Switchgear is the world Presented By John Byrd at 2014 ASCO Annual Meeting. Background. Presented By John Byrd at 2014 ASCO Annual Meeting. RESONATE™ Phase 3 Study Design. Presented By John Byrd at 2014 ASCO Annual Meeting. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Conflict of Interest Disclosure. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Limited Advancement in 2nd-Line Therapy. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Year in Review 2012. Colorectal Cancer. Daniel G Haller, MD. Professor of Medicine Emeritus. Abramson Cancer Center of the. University of Pennsylvania. Perelman School of Medicine at the. University of Pennsylvania. Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. Presented By James Hill at 2016 ASCO Annual Meeting. Learning Objectives for obstructing colorectal cancer. Presented By James Hill at 2016 ASCO Annual Meeting. Rationale of CREST – Converting emergency into elective surgery. Presented By Sham Mailankody at 2016 ASCO Annual Meeting. Massive genetic heterogeneity in <br />multiple myeloma. Presented By Sham Mailankody at 2016 ASCO Annual Meeting. Multiple myeloma consistently preceded by precursor states. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. Chemotherapy Alone for Unresectable . Locally Advanced Pancreatic Cancer . Supported by educational grants from AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo, Inc.. CCO Independent Conference Highlights*. San Francisco. , USA. Assoc. . Prof. . Shilpa Gupta. Cleveland Clinic, Ohio, USA. UROTHELIAL CANCER UPDATE. Please note: The views expressed within this presentation are the personal opinions of the author. They do not necessarily represent the views of the author’s academic institution or the rest of the GU CONNECT group.. Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . approach. . to. . HER 2 . breast. . cancer. . in . metastatic. . setting. Lisa Carey, SABCS 2018. La malattia HER2 positiva: . Trastuzumab. Key Phase III HER2 Positive MBC Trials.